Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2020-03-31 Audit Report / Informat…
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
5_Grupa_Kapitalowa_Pharmena_Sprawozdanie z działalności 2019 podpisane
Audit Report / Information Classification · 98% confidence The document is titled "Sprawozdanie Zarządu za 2019 rok" (Management Report for 2019) and contains a detailed table of contents covering financial data, business activities, strategy, significant events, management structure, legal proceedings, and remuneration details. The structure and content strongly indicate a comprehensive annual report, specifically the management's discussion and analysis section, which is a core component of a full annual filing. Given the context of Polish reporting (implied by the language) and the comprehensive nature covering the entire year (2019), this aligns best with the definition of an Annual Report (10-K equivalent in structure, though the code 10-K is typically for US SEC filings, the definition provided maps 'Annual Report' to '10-K'). Since the document is extensive (295,437 characters) and contains the full report content rather than just an announcement, it is classified as the report itself. FY 2019
2020-03-31 Polish
4_PHARMENA_sprawozdanie skonsoldiowane_podpisane
Annual Report Classification · 100% confidence The document is a 'Consolidated Financial Statement' (Skonsolidowane sprawozdanie finansowe) for the year ended December 31, 2019, for Grupa Pharmena. It contains detailed financial tables, notes, and disclosures, which are characteristic of an annual financial report. Since it covers a full fiscal year and provides comprehensive financial statements, it is classified as an Annual Report (10-K). FY 2019
2020-03-31 Polish
3_BDO SzB skonsolidowane Pharmena 2019-sig-sig
Audit Report / Information Classification · 99% confidence The document is titled "Sprawozdanie niezależnego biegłego rewidenta z badania dla Walnego Zgromadzenia oraz Rady Nadzorczej Pharmena S.A." (Independent Auditor's Report on the Audit of the Annual Consolidated Financial Statements for the General Meeting and Supervisory Board of Pharmena S.A.) and contains the formal 'Opinia' (Opinion) section, detailing the audit procedures, responsibilities of management and the auditor, and referencing specific financial reporting standards (IFRS, Polish Accounting Act). This content is characteristic of a formal Audit Report, which includes the auditor's opinion on the financial statements. This aligns directly with the definition for 'Audit Report / Information' (AR). Although it relates to the annual period (ending Dec 31, 2019), the document itself is the auditor's opinion, not the full Annual Report (10-K) or the Earnings Release (ER). FY 2019
2020-03-31 Polish
2_PHARMENA_WYBRANE SKONSOLIDOWANE DANE FINANSOWE za 2019
Earnings Release Classification · 99% confidence The document presents detailed comparative financial data for the years 2019 and 2018, including key line items like 'Przychody ze sprzedaży' (Revenue), 'Zysk (strata) netto' (Net profit/loss), and balance sheet items ('Aktywa razem' - Total Assets). It also includes per-share data and currency conversion rates (PLN to EUR) used for the reporting period. This structure is characteristic of a comprehensive financial report covering a full fiscal year or a significant interim period. Since it covers full years (2019 vs 2018) and contains detailed statements (P&L, Cash Flow, Balance Sheet), it strongly suggests an Annual Report (10-K) or a comprehensive Interim Report (IR). Given the comparison across two full years and the depth of data, it aligns best with the scope of an Annual Report (10-K) or a very detailed Interim Report (IR). However, without explicit mention of '10-K' or 'Roczny' (Annual), and given the comprehensive nature covering a full year's comparison, 'IR' (Interim/Quarterly Report) is often used for detailed reports that aren't explicitly the 10-K filing, especially if this is a local statutory filing. Since it compares two full years, it leans towards the annual scope, but 'IR' is the closest fit for a comprehensive financial statement that isn't explicitly labeled as the 10-K. Given the Polish context and the detailed financial tables, this is a comprehensive financial statement. If it were a Q3 report, it would be IR. If it's the full year, it's closer to 10-K. Since it shows two full years, I will classify it as an Interim Report (IR) as it represents a detailed financial statement, which is the closest match for comprehensive financial data that isn't explicitly an ER (Earnings Release) or 10-K. FY 2019
2020-03-31 Polish
1_pismo_grupa_2019
Earnings Release Classification · 99% confidence The document is a letter from the CEO ('Prezes Zarządu') presenting the 'raport za 2019 rok' (report for 2019). It summarizes key financial results (revenues, loss), operational activities (R&D, new product launches, Amazon partnership), and future outlook. This content structure—a comprehensive review of the past year's performance and future strategy, often signed by management—is characteristic of an Annual Report (10-K) or a Management Discussion and Analysis (MDA) section thereof. Since the text provides detailed financial figures and operational narrative for the full year, it strongly suggests it is the core content of the Annual Report or a significant accompanying management discussion. Given the options, '10-K' (Annual Report) is the most appropriate classification for a full-year performance review, although it could also be considered an MDA if it were a standalone filing. However, the context implies this is the main yearly review document. The length (4255 chars) is substantial enough to be the report itself, not just a brief announcement (RPA). FY 2019
2020-03-31 Polish
9_Pharmena_Oświadczenie_RN_audytor_komitet audytu
Governance Information Classification · 95% confidence The document is titled "OŚWIADCZENIE DOTYCZĄCE POLITYKI WYBORU FIRMY AUDYTORSKIEJ" (Statement Regarding the Policy for Selecting an Audit Firm) and includes a section on the Audit Committee ("OŚWIADCZENIE W SPRAWIE KOMITETU AUDYTU"). It discusses the selection of the auditor (BDO Sp. z o.o.), compliance with rotation rules, and the functioning of the Audit Committee. This content directly relates to internal controls, governance practices, and the audit process, but it is not the full Audit Report itself (AR) nor the Annual Report (10-K). It is a specific declaration about the governance structure related to auditing. This aligns best with Governance Information (CGR), which covers internal rules and board structure, or potentially Audit Report/Information (AR) if interpreted broadly as information *about* the audit process, but CGR is a better fit for policy statements regarding selection and committee function.
2020-03-31 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.